MELA Sciences, Inc. [MELA], the medical device company that has developed MelaFind�,will visit the NASDAQ MarketSite in Times Square in recognition of Melanoma Monday� and to kick-off Melanoma/Skin Cancer Detection and Prevention Month�, as well as raise awareness about early detection of melanoma. Every hour, one American dies of melanoma and approximately fifteen are diagnosed with the disease.
In honor of the occasion, leading New York dermatologist Dr. Doris Day will ring the Opening Bell with Dr. Joseph Gulfo, President and CEO of MELA Sciences.
MELA Sciences will be supporting the American Academy of Dermatology’s Melanoma Monday early detection efforts by sponsoring free skin cancer screenings, which will be administered by board certified dermatologists onsite for NASDAQ staff, analysts and members of the media. The MelaFind device, a brand new medical technology that may be used by dermatologists to obtain additional information for a biopsy decision to detect melanoma, will be available to aid in the skin examinations.
Melanoma/Skin Cancer Detection and Prevention Month� and Melanoma Monday� are registered trademarks of the American Academy of Dermatology. The American Academy of Dermatology does not endorse or recommend any commercial products or services.
MELA Sciences is a medical device company focused on the commercialization of its flagship product, MelaFind�, and its further design and development. MelaFind is a non-invasive tool to provide additional information to dermatologists during melanoma skin examinations. The device uses light from visible to near-infrared wavelengths to evaluate skin lesions up to 2.5 mm beneath the skin. The device provides information on a lesion’s level of morphologic disorganization to provide additional objective information that may be used by dermatologists in the biopsy decision-making process. MelaFind has been approved by the US Food and Drug Administration for use in the US. In addition, MelaFind has received CE Mark approval and is approved for use in the European Union.
For more information on MELA Sciences, visit www.melasciences.com.
The NASDAQ OMX Group, Inc. is the world’s largest exchange company. It delivers trading, exchange technology and public company services across six continents, with more than 3,600 listed companies. NASDAQ OMX offers multiple capital raising solutions to companies around the globe, including its U.S. listings market, NASDAQ OMX Nordic, NASDAQ OMX Baltic, NASDAQ OMX First North, and the U.S. 144A sector. The company offers trading across multiple asset classes including equities, derivatives, debt, commodities, structured products and exchange-traded funds. NASDAQ OMX technology supports the operations of over 70 exchanges, clearing organizations and central securities depositories in more than 50 countries. NASDAQ OMX Nordic and NASDAQ OMX Baltic are not legal entities but describe the common offering from NASDAQ OMX exchanges in Helsinki, Copenhagen, Stockholm, Iceland, Tallinn, Riga, and Vilnius. For more information about NASDAQ OMX, visit https://www.nasdaqomx.com.